What is Entrectinib/Luo Shengquan used to treat?

Entrectinib (Entrectinib) is an oral small molecule tyrosine kinase inhibitor that mainly targets tumors driven by NTRK, ROS1 and ALK fusion genes and belongs to the category of precision targeted therapy. In the past few years, entrectinib has provided patients with a new treatment option for ALK- or ROS1-positive non-small cell lung cancer and NTRK fusion-driven solid tumors.

In the field of non-small cell lung cancer,ALK or ROS1-positive patients usually have limited response to traditional chemotherapy, while entrectinib inhibits downstream signaling pathways by irreversibly binding to fusion proteins, blocking tumor cell proliferation and survival. This mechanism enables it to show efficacy in patients who are previously resistant to ALK or ROS1 inhibitors or who are treatment-naïve, and at the same time, it can penetrate the central nervous system and delay the progression of brain metastasis.

For patients with NTRK fusion-positive solid tumorsentrectinib provides a tissue-non-specific targeted therapy. Such patients often have multiple tumor types, including soft tissue sarcoma, thyroid cancer, breast cancer, etc. After NTRK fusion is confirmed through genetic testing, entrectinib can be used as a first-line or later-line treatment option to precisely intervene against driver mutations, thereby improving treatment response rate and disease control rate.

The oral administration method and controllable safety of entrectinib make it suitable for long-term maintenance treatment. Patients can complete the medication at home, reducing the frequency of hospitalization and improving the quality of life. At the same time, the drug's ability to penetrate the central nervous system provides significant advantages for patients at risk of brain metastasis. Overall, entrectinib is a precisely targeted drug targeting specific genetic alterations, providing an effective, sustainable and personalized treatment option for patients with ALK, ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors.

Reference materials:https://www.roche.com/products/rozlytrek